Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide

Nuclear Medicine and Biology

Volumn 31, Issue 3, 2004, Pages 337-344

  Kuhnast, B ^a   Bodenstein, C ^a   Haubner, R ^a   Wester, H J ^a   Senekowitsch Schmidtke, R ^a   Schwaiger, M ^a   Weber, W A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

HWGF containing peptide; Imaging; Iodine 125; Matrix metalloproteinases

Indexed keywords

GELATINASE; GELATINASE A; GELATINASE B; HISTIDYLTRYPTOPHYLGLYCYLPHENYLALANINE; MATRIX METALLOPROTEINASE; PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EVALUATION; IN VITRO STUDY; ISOTOPE LABELING; LUNG CANCER; MOUSE; NONHUMAN; PROTEIN MODIFICATION;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; FEMALE; GELATINASES; IODINE RADIOISOTOPES; ISOTOPE LABELING; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 1542708209     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.10.011     Document Type: Article

References (37)

1. Berzofsky J.A. Mechanisms of antigen-specific, genetically restricted, T cell-B cell interaction. Surv Immunol Res. 3:1984;103-106.
2. Bremer C., Tung C.H., Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 7:2001;743-748.
3. Brown P.D. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs. 9:2000;2167-2177.
4. Bruehlmeier M., Garayoa E., Blanc A., Holzer B., Gergely S., Tourwe D., Schubiger P., Blauenstein P. Stabilization of neurotensin analogues effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol. 29:2002;321-327.
5. Bunnett N.W., Reeve J.R., Walch J.H. Catabolism of bombesin in the interstitial fluid of the rat stomach. Neuropeptides. 4:1983;55-64.
6. Curran S., Murray G.I. Matrix metalloproteinases molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 36:2000;1621-1630.
7. Davies D.R., Sheriff S., Padlan E.A. Antibody-antigen complexes. J Biol Chem. 5:1998;10541-10544.
8. Drummond A.H., Beckett P., Brown P.D., Bone E.A., Davidson A.H., Galloway W.A., Gearing A.J., Huxley P., Laber D., McCourt M., Whittaker M., Wood L.M., Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci. 878:1999;228-235.
9. Dwyer D.S., Ardizzone T.D. Mimicry of dimerization by synthetic peptides designed to target homologous regions of proteins. Proteomics. 3:2003;317-324.
10. Foda H.D., Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today. 6:2001;478-482.
11. Garcia-Garayoa E., Blauenstein P., Bruehlmeier M., Blanc A., Iterbeke K., Conrath P., Tourwe D., Schubiger P.A. Preclinical evaluation of a new, stabilized neurotensin(8-13) pseudopeptide radiolabeled with (99m)tc. J Nucl Med. 43:2002;374-383.
12. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases structure, regulation and biological functions. Eur J Cell Biol. 74:1997;111-122.
13. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., Stocklin G., Schwaiger M. Radiolabeled alpha(v)beta3 integrin antagonists a new class of tracers for tumor targeting. J Nucl Med. 40:1999;1061-1071.
14. Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., Kessler H., Schwaiger M. Glycosylated RGD-containing peptides tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 42:2001;326-336.
15. Haubner R., Wester H.J., Weber W.A., Mang C., Ziegler S.I., Goodman S.L., Senekowitsch-Schmidtke R., Kessler H., Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:2001;1781-1785.
16. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93:2001;178-193.
17. Himelstein B.P., Canete-Soler R., Bernhard E.J., Dilks D.W., Muschel R.J. Metalloproteinases in tumor progression the contribution of MMP-9. Invasion Metastasis. 14:1994;246-258.
18. Iwata H., Kobayashi S., Iwase H., Masaoka A., Fujimoto N., Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res. 87:1996;602-611.
19. Kahari V.M., Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 31:1999;34-45.
20. Kok R.J., Schraa A.J., Bos E.J., Moorlag H.E., Asgeirsdottir S.A., Everts M., Meijer D.K., Molema G. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug Chem. 13:2003;128-135.
21. Koenig J.A., Edwardson J.M., Humphrey P.P. Somatostatin receptors in Neuro2A neuroblastoma cells ligand internalization. Br J Pharmacol. 120:1997;52-59.
22. Koenig J.A., Kaur R., Dodgeon I., Edwardson J.M., Humphrey P.P. Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J. 336:1998;291-298.
23. Koivunen E., Arap W., Valtanen H., Rainisalo A., Medina O.P., Heikkila P., Kantor C., Gahmberg C.G., Salo T., Konttinen Y.T., Sorsa T., Ruoslahti E., Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 17:1999;768-774.
24. Leisner M., Kessler H., Schwaiger M., Wester H.J. Synthesis of N-D-Phe-Amadori derivates for Tyr-Octreotide: Precursors for 123I and 18F-labeled SSTR-binding SPECT/PET tracers with improved biokinetics. J Labelled Cpd Radiopharm. 42:(Suppl 1):1999;S549-S551.
25. Medina O.P., Soderlund T., Laakkonen L.J., Tuominen E.K., Koivunen E., Kinnunen P.K. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 61:2001;3978-3985.
26. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 2:1996;461-462.
27. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 185:1998;256-261.
28. Murray G.I., Duncan M.E., Arbuckle E., Melvin W.T., Fothergill J.E. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut. 43:1998;791-797.
29. Nakamura H., Ueno H., Yamashita K., Shimada T., Yamamoto E., Noguchi M., Fujimoto N., Sato H., Seiki M., Okada Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 59:1999;467-473.
30. Ray J.M., Stetler-Stevenson W.G. Gelatinase. A activity directly modulates melanoma cell adhesion, and spreading. Embo J. 14:1995;908-917.
31. Rha S.Y., Yang W.I., Kim J.H., Roh J.K., Min J.S., Lee K.S., Kim B.S., Chung H.C. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep. 5:1998;875-879.
32. Skiles J.W., Gonnella N.C., Jeng A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem. 8:2001;425-474.
33. Skotnicki J.S., Zask A., Nelson F.C., Albright J.D., Levin J.I. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci. 878:1999;61-72.
34. Wang L.X., Ni J., Singh S. Carbohydrate-centered maleimide cluster as a new type of templates for multivalent peptide assembling. synthesis of multivalent HIV-1 gp41 peptides. Bioorg Med Chem. 11:2003;159-166.
35. Wester H.J., Schottelius M., Scheidhauer K., Reubi J.C., Wolf I., Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA the effect of carbohydration on the pharmacokinetics. Eur J. Nucl. Med. Mol Imaging. 29:2002;28-38.
36. Whittaker M., Floyd C.D., Brown P., Gearing A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 99:1999;2735-2776.
37. Yu A.E., Hewitt R.E., Kleiner D.E., Stetler-Stevenson W.G. Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2. Biochem Cell Biol. 74:1996;823-831.